Search - tctmd.com

Displaying 1 - 20 of 521

Sort: Relevancy | Date

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Available Devices/Techniques for Closure of PFO

Presenter: John D. Carroll, Christian Spies, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

The Case for Surgery

Presenter: Michael A. Borger, Vinod H. Thourani, Martin Misfeld

November 01, 2016

Presentation TCT 2016

Case #3 - Resolution: Did We Close It (?), and Long-term Patient Outcomes

Presenter: John D. Carroll, David E. Thaler, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

The Case for Transcatheter Therapy

Presenter: Michael A. Borger, Vinod H. Thourani, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

The Case for a Trial of Medical Therapy

Presenter: John A. Bittl, David J. Maron, Michael E. Farkouh

November 01, 2016

Presentation TCT 2016

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? Yes, Even if Only to Avoid a Disfiguring Sternotomy!

Presenter: Andreas Baumbach, David Hildick-Smith, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Presenter: George D. Dangas, Debabrata Mukherjee, C. Michael Gibson

November 01, 2016

Advertisement

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Available Devices/Techniques for Closure of PFO

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

FDA Perspectives on Short DAPT IDE Trials

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

The Case for Surgery

Case #3 - Resolution: Did We Close It (?), and Long-term Patient Outcomes

The Case for Transcatheter Therapy

The Case for a Trial of Medical Therapy

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? Yes, Even if Only to Avoid a Disfiguring Sternotomy!

Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content